Transaction · 0001746473-26-000117

Raben David

Raben David, CMO, reported a transaction classified as grant at PLIANT THERAPEUTICS, INC. involving 575000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 575000.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACMO
PLRXPLIANT THERAPEUTICS, INC.
Filing timeOct 02
Trade dateOct 01, 2026
Filing · SECView on SEC
InsiderProfile
% of reported position tradedUnavailableNot calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
—
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

PLRX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
PLRX since 2026-10-02Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001746473-26-000117
Stock Option (Right to Buy)
Transaction date
Oct 01, 2026
Filed Oct 02, 2026, 08:20 PM · 1d delay
Shares
575k sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
575k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Increase
-6score
Filing-only score

-6

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Medical Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Twenty-five percent (25%) of the shares subject to such option vest and become exercisable on September 30, 2027, and the remaining seventy-five percent (75%) of the shares subject to the option vest…

Original filing · 0001746473-26-000117
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

PLRX